The most common on-treatment , severe-intensity adverse event in both studies was acute exacerbation of COPD ( @-@ -LSB- < @-@ % -RSB- patients across treatment groups in study @ and @-@ -LSB- < @-@ % -RSB- patients in study @ ) .